Payment overview · 2025
General Payments
$148.16
8 reported records · 7 companies
Healthcare provider profile · identity verified
Matthew R Reetz, DO
Allopathic & Osteopathic Physicians|Family Medicine · DOVER, DE · NPI 1306028048
Verified facts
What the public records show
CMS Open Payments records show Matthew R Reetz, DO received $148.16 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.15 | 19.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.53 | 15.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.96 | 14.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.00 | 14.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 13.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.68 | 11.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.46 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.16 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 641 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 120 |
| Lisinopril | Lisinopril | 416 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 63 |
| Losartan Potassium | Losartan Potassium | 188 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 60 |
| Metformin Hcl | Metformin Hcl | 159 | 51 |
| Furosemide | Furosemide | 155 | 48 |
| Gabapentin | Gabapentin | 137 | 46 |
| Omeprazole | Omeprazole | 130 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 44 |
| Sertraline Hcl | Sertraline Hcl | 117 | 34 |
| Montelukast Sodium | Montelukast Sodium | 114 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 39 |
| Simvastatin | Simvastatin | 109 | 37 |
| Jardiance | Empagliflozin | 99 | 22 |
| Alprazolam | Alprazolam | 94 | 28 |
| Metformin Hcl Er | Metformin Hcl | 89 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 26 |
| Ozempic | Semaglutide | 66 | 18 |
| Meloxicam | Meloxicam | 64 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 24 |
| Lovastatin | Lovastatin | 63 | 17 |
| Atenolol | Atenolol | 62 | 21 |
| Carvedilol | Carvedilol | 62 | 22 |
| Synthroid | Levothyroxine Sodium | 62 | 17 |
| Trazodone Hcl | Trazodone Hcl | 61 | 19 |
| Tramadol Hcl | Tramadol Hcl | 59 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 16 |
| Allopurinol | Allopurinol | 56 | 17 |
| Eliquis | Apixaban | 55 | 16 |
| Famotidine | Famotidine | 52 | 20 |
| Prednisone | Prednisone | 51 | 34 |
| Farxiga | Dapagliflozin Propanediol | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 20 |
| Ibuprofen | Ibuprofen | 47 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 25 |
| Potassium Chloride | Potassium Chloride | 43 | 18 |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 15 |
| Alendronate Sodium | Alendronate Sodium | 40 | 16 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Ketoconazole | Ketoconazole | 37 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 24 |
| Azithromycin | Azithromycin | 36 | 33 |
| Januvia | Sitagliptin Phosphate | 36 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Finasteride | Finasteride | 31 | 11 |
| Topiramate | Topiramate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 24 |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.16 · 8 records | Lilly USA, LLC | ENFLONSIA, FARXIGA, JARDIANCE, KISUNLA, ROTATEQ, The Cologuard Plus Collection Kit, VAXNEUVANCE, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error